Each year at American Society of Hematology (ASH) Annual Meeting and Exposition, physicians and scientists from around the world come together to present hematology research updates and discuss the latest treatments for blood cancers and blood disorders.
This year, the 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place December 9-13 as a hybrid conference, with attendance both in-person in New Orleans and virtually.
The meeting featured exciting new research from physicians and scientists, including our team members who were involved with important research for myeloma and related plasma cell disorders.
The Weill Cornell Medicine (WCM) Myeloma Center was involved with numerous abstracts presented at ASH 2022. We are dedicated to developing the best possible treatments and cures for these diseases and proud to continue to contribute to efforts to move advances forward.
Director of the Weill Cornell Medicine Myeloma Center, Dr. Ruben Niesvizky, details research involving the use of a unique platform to determine whether multiple myeloma patients with relapsed/refractory disease could be more likely to respond to some immunotherapies over others.
Research from the Weill Cornell Medicine Myeloma Center and the Multiple Myeloma Research Foundation (MMRF) registry looked at a subset of multiple myeloma patients with disease outside the bone marrow. Third year Hematology & Oncology Fellow Dr. Mateo Mejia breaks down the findings of this project.
Dr. Ruben Niesvizky shares the implications of a clinical trial utilizing immune profiling for newly diagnosed multiple myeloma patients and how this process can help define outcomes for a subset of patients.
Dr. Monica Guzman, along with collaborators around the country, analyzed novel therapeutic targets for multiple myeloma and how these targets can be applied as potential treatments for these patients.
The Weill Cornell Medicine Myeloma Center was involved with a phase two clinical trial evaluating the bispecific antibody elranatamab for relapsed/refractory multiple myeloma. Dr. Ruben Niesvizky shares insights into the results of this study.
Dr. Mateo Mejia shares details about an observational study exploring differences between younger and older multiple myeloma patients.
Initial reports from a phase one clinical trial show promising results using the investigational monoclonal antibody, SEA-BCMA for a subset of multiple myeloma patients. Dr. Ruben Niesvizky details these results.
The Weill Cornell Medicine Myeloma Center team was honored to have been selected to share our expertise at the 2022 ASH annual meeting. We continue to work throughout the year on these research initiatives for the betterment of our patients and those will multiple myeloma around the world.